Worth reading
68In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationFiscal year ended February 2026 (41st fiscal year)13 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥128,794 million+3.5%
Operating profit¥31,154 million-2.7%
Ordinary income¥32,621 million-8.0%
Net income¥19,048 million-19.4%
Operating profit margin24%, down 2 percentage points year on year
Selling, general and administrative expensesHigher personnel expenses, research and development expenses, amortization of goodwill and other selling, general and administrative expenses were disclosed. The SG&A ratio to revenue was not disclosed.
Results for the three months of the current quarterQ4 revenue: semiconductor-related equipment, ¥26,800 million; analytical equipment, ¥1,344 million; FPD-related equipment, ¥2,348 million; life sciences-related equipment, ¥732 million; parts, repairs and other, ¥3,084 million. Q4 orders for semiconductor-related equipment were ¥34,004 million.
Full-year earnings forecast
Fiscal year ending February 2027Revenue of ¥159,021 million, operating income of ¥38,112 million, ordinary income of ¥38,241 million and net income attributable to owners of the parent of ¥27,809 million. Semiconductor-related equipment, ¥132,480 million; analytical equipment, ¥4,225 million; FPD-related equipment, ¥10,090 million; life sciences-related equipment, ¥1,588 million; parts, repairs and other, ¥10,636 million.
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。Fiscal year ended February 2026 actual results as a percentage of the full-year plan: revenue, 100.5%; semiconductor-related equipment, 99.5%; analytical equipment, 85.4%; FPD-related equipment, 96.2%; life sciences-related equipment, 75.6%; parts, repairs and other, 126.7%; operating income, 102.7%; ordinary income, 106.5%; net income attributable to owners of the parent, 81.1%.
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Change in operating income from ¥32,024 million in the previous fiscal year to ¥31,154 million in the current fiscal year: change in revenue, +¥3,046 million; foreign exchange impact, -¥12 million; personnel expenses, -¥1,577 million; research and development expenses, -¥685 million; amortization of goodwill, -¥1,427 million; other selling, general and administrative expenses, -¥213 million.
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
The outlook assumes an exchange rate of ¥159/USD, wider adoption and use of generative AI, increased semiconductor demand, and concentrated investment in advanced logic, HBM and advanced packaging.New initiatives
Construction of a new plant and expansion of production capacity at the Vietnam plant; expansion of analytical equipment applications to semiconductor device production, in-line inspection of manufacturing equipment and materials inspection; rollout of the new Expert_LA laser ablation equipment; and development of vacuum transfer equipment, transfer equipment for advanced packaging and next-generation products.Key KPIsA metric the company considers important as a management benchmark.
Q4 orders for semiconductor-related equipment were ¥34,004 million, up 48% quarter on quarter and a record high. Full-year sales in Taiwan were 1.8 times the previous fiscal year's level. Semiconductor-related equipment accounted for 83% of sales, with end users accounting for 27% and equipment manufacturers for 73%.Segment results
Revenue by product: semiconductor-related equipment, ¥106,345 million (103.9% year on year); analytical equipment, ¥3,554 million (90.1%); FPD-related equipment, ¥6,298 million (73.3%); life sciences-related equipment, ¥1,201 million (111.8%); parts, repairs and other, ¥11,395 million (135.3%). Operating income by product was not disclosed.Risk amount incorporated into the outlookThe amount representing the range of variation the company expects in its forecast.
Not disclosed. Uncertain litigation-related expenses have not been included in the initial plan.Orders received and order backlog
Orders for semiconductor-related equipment in the quarter were ¥34,004 million, with an order backlog of ¥50,461 million. Q4 orders for analytical equipment were ¥1,460 million, with an order backlog of ¥3,196 million. Q4 orders for FPD-related equipment were ¥2,572 million, with an order backlog of ¥1,678 million.Number of stores and locations
5 domestic locations. Overseas locations: the United States, Vietnam, Taiwan, South Korea, Singapore, China, Germany and France. The number of openings and closures during the period was not disclosed.Number of employees
Consolidated: 4,547 employees; the company: 361 employees (as of the end of February 2026). Consolidated headcount increased by 14 from the previous quarter.Capital expenditures
¥11,982 million fiscal year ending February 2027 plan
Annual Dividend
The breakdown of the annual dividend was not disclosed. The year-end dividend was ¥17 per share for the fiscal year ended February 2026, with a forecast of ¥20 per share for the fiscal year ending February 2027.Payout ratio
Not disclosed. The company stated that its policy is to pay stable dividends.Acquisition of treasury shares
Acquisition value: ¥5,000 million, completed at the end of July 2025. The number of shares acquired and acquisition period were not disclosed.| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Fiscal year ended February 2026 (41st fiscal year) |
| Net Sales | ¥128,794 million (YoY +3.5%) |
| Operating profit | ¥31,154 million (YoY -2.7%) |
| Ordinary income | ¥32,621 million (YoY -8.0%) |
| Net income | ¥19,048 million (YoY -19.4%) |
| Operating profit margin | 24%, down 2 percentage points year on year |
| Selling, general and administrative expenses | Higher personnel expenses, research and development expenses, amortization of goodwill and other selling, general and administrative expenses were disclosed. The SG&A ratio to revenue was not disclosed. |
| Results for the three months of the current quarter | Q4 revenue: semiconductor-related equipment, ¥26,800 million; analytical equipment, ¥1,344 million; FPD-related equipment, ¥2,348 million; life sciences-related equipment, ¥732 million; parts, repairs and other, ¥3,084 million. Q4 orders for semiconductor-related equipment were ¥34,004 million. |
| Full-year earnings forecast | Fiscal year ending February 2027 Revenue of ¥159,021 million, operating income of ¥38,112 million, ordinary income of ¥38,241 million and net income attributable to owners of the parent of ¥27,809 million. Semiconductor-related equipment, ¥132,480 million; analytical equipment, ¥4,225 million; FPD-related equipment, ¥10,090 million; life sciences-related equipment, ¥1,588 million; parts, repairs and other, ¥10,636 million. |
| Progress against full-year forecast | Fiscal year ended February 2026 actual results as a percentage of the full-year plan: revenue, 100.5%; semiconductor-related equipment, 99.5%; analytical equipment, 85.4%; FPD-related equipment, 96.2%; life sciences-related equipment, 75.6%; parts, repairs and other, 126.7%; operating income, 102.7%; ordinary income, 106.5%; net income attributable to owners of the parent, 81.1%. |
| Segment results | Revenue by product: semiconductor-related equipment, ¥106,345 million (103.9% year on year); analytical equipment, ¥3,554 million (90.1%); FPD-related equipment, ¥6,298 million (73.3%); life sciences-related equipment, ¥1,201 million (111.8%); parts, repairs and other, ¥11,395 million (135.3%). Operating income by product was not disclosed. |
| Breakdown of Factors Affecting the Change | Change in operating income from ¥32,024 million in the previous fiscal year to ¥31,154 million in the current fiscal year: change in revenue, +¥3,046 million; foreign exchange impact, -¥12 million; personnel expenses, -¥1,577 million; research and development expenses, -¥685 million; amortization of goodwill, -¥1,427 million; other selling, general and administrative expenses, -¥213 million. |
| Key KPIs | Q4 orders for semiconductor-related equipment were ¥34,004 million, up 48% quarter on quarter and a record high. Full-year sales in Taiwan were 1.8 times the previous fiscal year's level. Semiconductor-related equipment accounted for 83% of sales, with end users accounting for 27% and equipment manufacturers for 73%. |
| Number of stores and locations | 5 domestic locations. Overseas locations: the United States, Vietnam, Taiwan, South Korea, Singapore, China, Germany and France. The number of openings and closures during the period was not disclosed. |
| Number of employees | Consolidated: 4,547 employees; the company: 361 employees (as of the end of February 2026). Consolidated headcount increased by 14 from the previous quarter. |
| Assumptions Underlying the Business Outlook | The outlook assumes an exchange rate of ¥159/USD, wider adoption and use of generative AI, increased semiconductor demand, and concentrated investment in advanced logic, HBM and advanced packaging. |
| Risk amount incorporated into the outlook | Not disclosed. Uncertain litigation-related expenses have not been included in the initial plan. |
| Annual Dividend | The breakdown of the annual dividend was not disclosed. The year-end dividend was ¥17 per share for the fiscal year ended February 2026, with a forecast of ¥20 per share for the fiscal year ending February 2027. |
| Payout ratio | Not disclosed. The company stated that its policy is to pay stable dividends. |
| Acquisition of treasury shares | Acquisition value: ¥5,000 million, completed at the end of July 2025. The number of shares acquired and acquisition period were not disclosed. |
| Capital expenditures | ¥11,982 million (fiscal year ending February 2027 plan) |
| Orders received and order backlog | Orders for semiconductor-related equipment in the quarter were ¥34,004 million, with an order backlog of ¥50,461 million. Q4 orders for analytical equipment were ¥1,460 million, with an order backlog of ¥3,196 million. Q4 orders for FPD-related equipment were ¥2,572 million, with an order backlog of ¥1,678 million. |
| New initiatives | Construction of a new plant and expansion of production capacity at the Vietnam plant; expansion of analytical equipment applications to semiconductor device production, in-line inspection of manufacturing equipment and materials inspection; rollout of the new Expert_LA laser ablation equipment; and development of vacuum transfer equipment, transfer equipment for advanced packaging and next-generation products. |
Items this document does not state (7)
Gross Profit MarginSelf-assessment against the planUnit price and quantity metricsMedium-term management plan targetsFinancial targetsMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended February 2026, higher sales of semiconductor-related equipment and parts and repair services contributed to the increase in revenue. The decline in operating income was attributable to higher selling, general and administrative expenses, including personnel expenses, research and development expenses and amortization of goodwill. The decline in ordinary income was due to lower foreign exchange gains, while the decline in net income was due to the recording of ¥7,429 million in provision for litigation losses related to litigation in the United States. For the fiscal year ending February 2027, higher orders for semiconductor-related equipment are expected to drive revenue growth.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.